Changes in brain-derived neurotrophic factor (BDNF) during abstinence could be associated with relapse in cocaine-dependent patients

Psychiatry Research

Volumn 225, Issue 3, 2015, Pages 309-314

  Corominas Roso, Margarida ^a   Roncero, Carlos ^a,b,c   Daigre, Constanza ^a   Grau Lopez, Lara ^a,c   Ros Cucurull, Elena ^a,c   Rodríguez Cintas, Laia ^a   Sanchez Mora, Cristina ^a,b,d   Lopez, Maria Victoria ^a   Ribases, Marta ^a,b,d   Casas, Miguel ^a,b,c  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Abstinence; BDNF; Brain derived neurotrophic factor; Cocaine; Relapse

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; COCAINE;

ABSTINENCE; ADULT; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CLINICAL ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; MOLECULAR DYNAMICS; OUTCOME ASSESSMENT; PREDICTION; PROTEIN DETERMINATION; PROTEIN FUNCTION; RELAPSE; RISK ASSESSMENT; RISK FACTOR; YOUNG ADULT; ADOLESCENT; BLOOD; CHRONIC DISEASE; DEPRESSION; DRUG SEEKING BEHAVIOR; PSYCHOLOGY; RECURRENT DISEASE; WITHDRAWAL SYNDROME;

ADOLESCENT; ADULT; BRAIN-DERIVED NEUROTROPHIC FACTOR; CHRONIC DISEASE; COCAINE; COCAINE-RELATED DISORDERS; DEPRESSION; DRUG-SEEKING BEHAVIOR; FEMALE; HUMANS; MALE; MIDDLE AGED; RECURRENCE; SUBSTANCE WITHDRAWAL SYNDROME; YOUNG ADULT;

EID: 84922840331     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2014.12.019     Document Type: Article

References (51)

1. Aicardi G., Argilli E., Cappello S., Santi S., Riccio M., Thoenen H., Canossa M. Induction of long-term potentiation and depression is reflected by corresponding changes in secretion of endogenous brain-derived neurotrophic factor. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:15788-15792.
2. Alhaider I.A., Aleisa A.M., Tran T.T., Alkadhi K.A. Sleep deprivation prevents stimulation-induced increases of levels of P-CREB and BDNF: protection by caffeine. Mol Cell Neurosci 2011, 46:742-751.
3. Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression. Archives of General Psychiatry 1961, 4:561-571.
4. Bramham C.R., Messaoudi E. BDNF function in adult synaptic plasticity: the synaptic consolidation hypothesis. Progress in Neurobiology 2005, 76:99-125.
5. Briand L.A., Lee F.S., Blendy J.A., Pierce R.C. Enhanced extinction of cocaine seeking in brain-derived neurotrophic factor Val66Met knock-in mice. The European Journal of Neuroscience 2012, 35:932-939.
6. Capiotti KM., Menezes FP., Nazario LR., Pohlmann JB., de Oliveira GM., Fazenda L., Bogo MR., Bonan CD., Da Silva RS. Early exposure to caffeine affects gene expression of adenosine receptors, DARPP-32 and BDNF without affecting sensibility and morphology of developing zebrafish (Danio rerio). Neurotoxicol Teratol 2011, 33:680-685.
7. Chen Z.Y., Patel P.D., Sant G., Meng C.X., Teng K.K., Hempstead B.L., Lee F.S. Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons. The Journal of Neuroscience 2004, 24:4401-4411.
8. Cheng C.Y., Hong C.J., Yu Y.W.Y., Chen T.J., Wu H.C., Tsai S.J. Brain-derived neurotrophic factor (Val66Met) genetic polymorphism is associated with substance abuse in males. Brain Research. Molecular Brain Research 2005, 140:86-90.
9. Chhatwal J.P., Stanek-Rattiner L., Davis M., Ressler K.J. Amygdala BDNF signaling is required for consolidation but not encoding of extinction. Nature Neuroscience 2006, 9:870-882.
10. Corominas-Roso M., Roncero C., Eiroa-Orosa F.J., Gonzalvo B., Grau-Lopez L., Ribases M., Rodriguez-Cintas L., Sánchez-Mora C., Ramos-Quiroga J.A., Casas M. Brain-derived neurotrophic factor serum levels in cocaine-dependent patients during early abstinence. European Neuropsychopharmacology 2013, 23:1078-1084.
11. Dietz D.M., Dietz K.C., Nestler E.J., Russo S.J. Molecular mechanisms of psychostimulant-induced structural plasticity. Pharmacopsychiatry 2009, 42(Suppl, 1):S69-S78.
12. D'Sa C., Fox H.C., Hong A.K., Dileone R.J., Sinha R. Increased serum brain-derived neurotrophic factor is predictive of cocaine relapse outcomes: a prospective study. Biological Psychiatry 2011, 70:706-711.
13. Duman R.S., Aghajanian G.K. Neurobiology of rapid acting antidepressants: role of BDNF and GSK-3β. Neuropsychopharmacology 2014, 39:233.
14. Ferreira A.F.B., Real C.C., Rodrigues A.C., Alves A.S., Britto L.R.G. Short-term, moderate exercise is capable of inducing structural, bdnf-independent hippocampal plasticity. Brain Research 2011, 1425:111-122.
15. Filip M., Faron-Górecka A., Kuśmider M., Gołda A., Frankowska M., Dziedzicka-Wasylewska M. Alterations in BDNF and trkB mRNAs following acute or sensitizing cocaine treatments and withdrawal. Brain Research 2006, 1071:218-225.
16. Fumagalli F., Caffino L., Racagni G., Riva M.A. Repeated stress prevents cocaine-induced activation of BDNF signaling in rat prefrontal cortex. European Neuropsychopharmacology 2009, 19:402-408.
17. Giannotti G., Caffino L., Calabrese F., Racagni G., Riva M.A., Fumagalli F. Prolonged abstinence from developmental cocaine exposure dysregulates BDNF and its signaling network in the medial prefrontal cortex of adult rats. International Journal of Neuropsychopharmacology 2014, 17:625-634.
18. Godar R., Dai Y., Bainter H., Billington C., Kotz C.M., Wang C.F. Reduction of high-fat diet-induced obesity after chronic administration of brain-derived neurotrophic factor in the hypothalamic ventromedial nucleus. Neuroscience 2011, 194:36-52.
19. Goodman L.J., Valverde J., Lim F., Geschwind M.D., Federoff H.J., Geller A.I., Hefti F. Regulated release and polarized localization of brain-derived neurotrophic factor in hippocampal neurons. Molecular and Cellular Neuroscience 1996, 7:222-238.
20. Grau-López L., Roncero C., Daigre C., Gonzalvo B., Bachiller D., Rodriguez-Cintas L., Egido A., Casas M. Risk factors for relapse in drug-dependent patients after hospital detoxification. Adicciones 2012, 24:115-122.
21. Grimm J.W., Lu L., Hayashi T., Hope B.T., Su T.-P., Shaham Y. Time-dependent increases in brain-derived neurotrophic factor protein levels within the mesolimbic dopamine system after withdrawal from cocaine: implications for incubation of cocaine craving. The Journal of Neuroscience 2003, 23:742-747.
22. Hall F.S., Drgonova J., Goeb M., Uhl G.R. Reduced behavioral effects of cocaine in heterozygous brain-derived neurotrophic factor (BDNF) knockout mice. Neuropsychopharmacology 2003, 28:1485-1490.
23. Heldt S.A., Stanek L., Chhatwal J.P., Ressler K.J. Hippocampus-specific deletion of BDNF in adult mice impairs spatial memory and extinction of aversive memories. Molecular Psychiatry 2007, 12:656-670.
24. Horger B.A., Iyasere C.A., Berhow M.T., Messer C.J., Nestler E.J., Taylor J.R. Enhancement of locomotor activity and conditioned reward to cocaine by brain-derived neurotrophic factor. The Journal of Neuroscience 1999, 19:4110-4122.
25. Huang T.L., Hung Y.Y. Lorazepam reduces the serum brain-derived neurotrophic factor level in schizophrenia patients with catatonia. Progress in Neuropsychopharmacology and Biological Psychiatry 2009, 33:158-159.
26. Jiang R., Brummett B.H., Babyak M.A., Siegler I.C., Williams R.B. Brain-derived neurotrophic factor (BDNF) Val66Met and adulthood chronic stress interact to affect depressive symptoms. The Journal of Psychiatry Research 2013, 47:233-239.
27. Kampman K.M., Volpicelli J.R., McGinnis D.E., Alterman A.I., Weinrieb R.M., D'Angelo L., Epperson L.E. Reliability and validity of the Cocaine Selective Severity Assessment. Addictive Behaviors 1998, 23:449-461.
28. Karege F., Schwald M., Cisse M. Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neuroscience Letters 2002, 328:261-264.
29. Klein A.B., Williamson R., Santini M.A., Clemmensen C., Ettrup A., Rios M., Knudsen G.M., Aznar S. Blood BDNF concentrations reflect brain-tissue BDNF levels across species. International Journal of Neuropsychopharmacology 2011, 14:347-353.
30. Lang U.E., Hellweg R., Sander T., Gallinat J. The Met allele of the BDNF Val66Met polymorphism is associated with increased BDNF serum concentrations. Molecular Psychiatry 2009, 14:120-122.
31. Lee J.W., Brown E.S., Perantie D.C., Bobadilla L. A comparison of single-item visual analog scales with a Multiitem Likert-Type Scale for assessment of cocaine craving in persons with bipolar disorder. Addictive Disorders and Their Treatment 2002, 1:140-142.
32. Li C.S.R., Luo X., Sinha R., Rounsaville B.J., Carroll K.M., Malison R.T., Ding Y.S., Zhang S., Ide J.S. Increased error-related thalamic activity during early compared to late cocaine abstinence. Drug and Alcohol Dependence 2010, 109:181-189.
33. Lu L., Grimm J.W., Hope B.T., Shaham Y. Incubation of cocaine craving after withdrawal: a review of preclinical data. Neuropharmacology 2004, 47(Suppl. 1):S214-S226.
34. Luo J., Zhang L., Ning N., Jiang H., Yu S.Y. Neotrofin reverses the effects of chronic unpredictable mild stress on behavior via regulating BDNF, PSD-95 and synaptophysin expression in rat. Behavioural Brain Research 2013, 253:48-53.
35. Lyons WE., Mamounas LA., Ricaurte GA., Coppola V., Reid SW., Bora SH., Wihler C., Koliatsos V.E., Tessarollo L. Brain-derived neurotrophic factor-deficient mice develop aggressiveness and hyperphagia in conjunction with brain serotonergic abnormalities. Proc Natl Acad Sci 1999, 96:5239-5244.
36. Miczek K.A., Nikulina E.M., Shimamoto A., Covington H.E. Escalated or suppressed cocaine reward, tegmental BDNF, and accumbal dopamine caused by episodic versus continuous social stress in rats. The Journal of Neuroscience 2011, 31:9848-9857.
37. Mitoma M., Yoshimura R., Sugita A., Umene W., Hori H., Nakano H., Ueda N., Nakamura J. Stress at work alters serum brain-derived neurotrophic factor (BDNF) levels and plasma 3-methoxy-4-hydroxyphenylglycol (MHPG) levels in healthy volunteers: BDNF and MHPG as possible biological markers of mental stress?. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2008, 32:679-685.
38. Molendijk M.L., Bus BA., Spinhoven P., Penninx BW., Kenis G., Prickaerts J., Voshaar RC., Elzinga BM. Serum levels of brain-derived neurotrophic factor in major depressive disorder: State-trait issues, clinical features and pharmacological treatment. Mol Psychiatry 2011, 16:1088-1095.
39. Murakami S., Imbe H., Morikawa Y., Kubo C., Senba E. Chronic stress, as well as acute stress, reduces BDNF mRNA expression in the rat hippocampus but less robustly. Neuroscience Research 2005, 53:129-139.
40. Nestler E.J., Aghajanian G.K. Molecular and cellular basis of addiction. Science 1997, 278:58-63.
41. Pan W., Banks W.A., Fasold M.B., Bluth J., Kastin A.J. Transport of brain-derived neurotrophic factor across the blood-brain barrier. Neuropharmacology 1998, 37:1553-1561.
42. Preston K.L., Epstein D.H. Stress in the daily lives of cocaine and heroin users: relationship to mood, craving, relapse triggers, and cocaine use. Psychopharmacology 2011, 218:29-37.
43. Sadri-Vakili G., Kumaresan V., Schmidt H.D., Famous K.R., Chawla P., Vassoler F.M., Overland R.P., Xia E., Bass C.E., Terwilliger E.F., Pierce R.C., Cha J.H.J. Cocaine-induced chromatin remodeling increases brain-derived neurotrophic factor transcription in the rat medial prefrontal cortex, which alters the reinforcing efficacy of cocaine. The Journal of Neuroscience 2010, 30:11735-11744.
44. Sartorius A., Hellweg R., Litzke J., Vogt M., Dormann C., Vollmayr B., Danker-Hopfe H., Gass P. Correlations and discrepancies between serum and brain tissue levels of neurotrophins after electroconvulsive treatment in rats. Pharmacopsychiatry 2009, 42:270-276.
45. Sen S., Duman R., Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biological Psychiatry 2008, 64:527-532.
46. Spielberger C.D., Gorsuch R.L., Lushene R., Vagg P.R., Jacobs G.A. Manual for the State-Trait Anxiety Inventory 1983, Consulting Psychologists' Press, Palo Alto.
47. Spitzer R.L., Williams J.B., Gibbon M., First M.B. The Structured Clinical Interview for DSM-III-R (SCID). I: history, rationale, and description. Archives of General Psychiatry 1992, 49:624-629.
48. Tiffany S.T., Singleton E., Haertzen C.A., Henningfield J.E. The development of a cocaine craving questionnaire. Drug and Alcohol Dependence 1993, 34:19-28.
49. Von Diemen L., Kapczinski F., Sordi A.O., de Magalhães Narvaez J.C., Guimarães L.S.P., Kessler F.H.P., Pfaffenseller B., de Aguiar B.W., de Moura Gubert C., Pechansky F. Increase in brain-derived neurotrophic factor expression in early crack cocaine withdrawal. International Journal of Neuropsychopharmacology 2014, 17:33-40.
50. Washton A.M., Stone-Washton N. Abstinence and relapse in outpatient cocaine addicts. Journal of Psychoactive Drugs 1990, 22:135-147.
51. Williams J.B., Gibbon M., First M.B., Spitzer R.L., Davies M., Borus J., Howes M.J., Kane J., Pope H.G., Rounsaville B. The Structured Clinical Interview for DSM-III-R (SCID). II. Multisite test-retest reliability. Archives of General Psychiatry 1992, 49:630-636.